Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Toyota Global Sales Fall as China Demand Slumps 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
Amazon Secures 200 MW Wind Power Deals in Sweden 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Add as a preferred source on Google
CAMBRIDGE, Mass., April 10, 2018 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 6th Annual Cell & Gene Therapy Investor Day in New York, New York on Tuesday, April 17, 2018 at 9:25am Eastern Time.
The presentation will be live webcast at: http://arminvestorday.com/webcast/, and may be accessed from the news and events section of the Vericel website.
About Vericel Corporation
Vericel is a leader in advanced cell therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. For more information, please visit the company's website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2018 Vericel Corporation. All rights reserved.
(vcel-corp)
Global Media Contacts:
David Schull
Russo Partners LLC
+1 212-845-4271 (office)
+1 858-717-2310 (mobile)
[email protected]
Karen Chase
Russo Partners LLC
+1 646-942-5627 (office)
+1 917-547-0434 (mobile)
[email protected]
Investor Contacts:
Chad Rubin
The Trout Group
[email protected]
+1 (646) 378-2947
Lee Stern
The Trout Group
[email protected]
+1 (646) 378-2922
